Background The oligometastatic paradigm suggests that some patients with a limited number
of metastases might be cured if all lesions are eradicated. Evidence from randomised …

Background The standard of care for operable, stage I, non-small-cell lung cancer (NSCLC)
is lobectomy with mediastinal lymph node dissection or sampling. Stereotactic ablative …

PURPOSE The oligometastatic paradigm hypothesizes that patients with a limited number of
metastases may achieve long-term disease control, or even cure, if all sites of disease can …

Background Evidence from retrospective studies suggests that disease progression after first-line
chemotherapy for metastatic non-small-cell lung cancer (NSCLC) occurs most often at …

PURPOSE Our previously published findings reported that local consolidative therapy (LCT)
with radiotherapy or surgery improved progression-free survival (PFS) and delayed new …

PURPOSE To provide recommendations for the management of patients with metastatic
clear cell renal cell carcinoma (ccRCC). METHODS An Expert Panel conducted a systematic …

Purpose Long-term randomized data assessing the effect of ablative therapies in patients
with oligometastases are lacking. The Stereotactic Ablative Radiotherapy for the …

Background Stereotactic ablative radiotherapy (SABR) has emerged as a new treatment
option for patients with oligometastatic disease. SABR delivers precise, high-dose, …

BACKGROUND Stereotactic ablative radiotherapy (SABR) is an emerging therapy for
primary renal cell carcinoma. The authors assessed safety, efficacy, and survival in a multi‐…

Purpose Stereotactic ablative radiation therapy (SABR) is a guideline-specified treatment
option for early-stage lung cancer. However, significant posttreatment fibrosis can occur and …